Contributions
Abstract: 14
Type: Educational Session
Abstract Category: N/A
While T and B lymphocytes of the adaptive immune response are well characterized participants in the pathophysiology of multiple sclerosis (MS). Less highlighted but equally important are prominent roles of cells of innate immunity, particularly myeloid cells that include monocytes, macrophages and microglia. We will review the involvement and mechanisms of these myeloid cells in promoting injury in MS, particularly in the progressive phase of the disease. As well, we will discuss the vicious cycle of interactions between T/B and myeloid cells that exacerbates pathology. Against that background, a cautionary note is raised as myeloid cells also participate in repair responses, including the phagocytosis of myelin debris and the provision of trophic factors necessary for remyelination to occur. Finally, we assess the direct or indirect effects of current available MS medications on myeloid cells, and introduce other medications directed towards myeloid cells in MS.
Disclosure: The author's research has been funded by the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, and the Alberta Innovates - Health Solutions CRIO Team program.
Dr. Yong has received educational grants for the Alberta MS Network and the Canadian Neuroimmunology Knowledge Dissemination Series from Biogen Canada, EMD Serono, Hoffmann-La Roche, Novartis, Sanofi Genzyme and Teva Canada Innovation. He has received speaker's fees from Teva Neuroscience and Biogen.
Abstract: 14
Type: Educational Session
Abstract Category: N/A
While T and B lymphocytes of the adaptive immune response are well characterized participants in the pathophysiology of multiple sclerosis (MS). Less highlighted but equally important are prominent roles of cells of innate immunity, particularly myeloid cells that include monocytes, macrophages and microglia. We will review the involvement and mechanisms of these myeloid cells in promoting injury in MS, particularly in the progressive phase of the disease. As well, we will discuss the vicious cycle of interactions between T/B and myeloid cells that exacerbates pathology. Against that background, a cautionary note is raised as myeloid cells also participate in repair responses, including the phagocytosis of myelin debris and the provision of trophic factors necessary for remyelination to occur. Finally, we assess the direct or indirect effects of current available MS medications on myeloid cells, and introduce other medications directed towards myeloid cells in MS.
Disclosure: The author's research has been funded by the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, and the Alberta Innovates - Health Solutions CRIO Team program.
Dr. Yong has received educational grants for the Alberta MS Network and the Canadian Neuroimmunology Knowledge Dissemination Series from Biogen Canada, EMD Serono, Hoffmann-La Roche, Novartis, Sanofi Genzyme and Teva Canada Innovation. He has received speaker's fees from Teva Neuroscience and Biogen.